Comparative effects of sodium channel blockers in short term rat whole embryo culture

Toxicology and Applied Pharmacology

Volumn 272, Issue 2, 2013, Pages 306-312

  Nilsson, Mats F ^a   Sköld, Anna Carin ^b   Ericson, Ann Christin ^b   Annas, Anita ^b   Villar, Rodrigo Palma ^b   Cebers, Gvido ^c   Hellmold, Heike ^b   Gustafson, Anne Lee ^b   Webster, William S ^d  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cardiac function; Drugs during pregnancy; Embryonic physiology; Hazard identification; Sodium channel blocker

Indexed keywords

BUPIVACAINE; CALCIUM CHANNEL L TYPE; LIDOCAINE; NIFEDIPINE; TERFENADINE;

ANIMAL EXPERIMENT; ARTICLE; BRADYCARDIA; COMPARATIVE STUDY; CONTROLLED STUDY; EMBRYO; EMBRYO CULTURE; FOLLOW UP; HEART BLOCK; HEART CONTRACTION; HEART FUNCTION; HEART RATE; IMAGE ANALYSIS; IN VITRO STUDY; NONHUMAN; RAT;

CARDIAC FUNCTION; DRUGS DURING PREGNANCY; EMBRYONIC PHYSIOLOGY; HAZARD IDENTIFICATION; SODIUM CHANNEL BLOCKER;

ANIMALS; BRADYCARDIA; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, INVESTIGATIONAL; HEART; HEART BLOCK; HEART RATE; IMAGE PROCESSING, COMPUTER-ASSISTED; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; ORGAN CULTURE TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; SODIUM CHANNEL BLOCKERS; TIME FACTORS;

EID: 84883761469     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.06.023     Document Type: Article

References (41)

1. Ababneh D., Ritchie H., Webster W.S. Antidepressants cause bradycardia and heart block in GD 13 rat embryos in vitro. Birth Defects Res. B Dev. Reprod. Toxicol. 2012, 95:184-193.
2. Abela D., Ritchie H., Ababneh D., Gavin C., Nilsson M.F., Khan M.K., Carlsson K., Webster W.S. The effect of drugs with ion channel-blocking activity on the early embryonic rat heart. Birth Defects Res. B Dev. Reprod. Toxicol. 2010, 89:429-440.
3. Abrahamsson C., Carlsson L., Duker G. Lidocaine and nisoldipine attenuate almokalant-induced dispersion of repolarization and early after depolarizations in vitro. J. Cardiovasc. Electrophysiol. 1996, 7:1074-1081.
4. Bridgland-Taylor M.H., Hargreaves A.C., Easter A., Orme A., Henthorn D.C., Ding M., Davis A.M., Small B.G., Heapy C.G., Abi-Gerges N., Persson F., Jacobson I., Sullivan M., Albertson N., Hammond T.G., Sullivan E., Valentin J.P., Pollard C.E. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. J. Pharmacol. Toxicol. Methods 2006, 54:189-199.
5. Carmeliet E. Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide. J. Pharmacol. Exp. Ther. 1992, 262:809-817.
6. Chantest® Human Cav1.2/β2/α2δ1 calcium channel cell line Available at, (Accessed). http://www.chantest.com/human-cav1-2-2-2-calcium-channel-cell-line.html.
7. Danielsson B.R., Skold A.C., Johansson A., Dillner B., Blomgren B. Teratogenicity by the hERG potassium channel blocking drug almokalant: use of hypoxia marker gives evidence for a hypoxia-related mechanism mediated via embryonic arrhythmia. Toxicol. Appl. Pharmacol. 2003, 193:168-176.
8. Doubilet P.M., Benson C.B. Outcome of first-trimester pregnancies with slow embryonic heart rate at 6-7weeks gestation and normal heart rate by 8weeks at US. Radiology 2005, 236:643-646.
9. Du X., Lu D., Daharsh E.D., Yao A., Dewoody R., Yao J.A. Dimethyl sulfoxide effects on hERG channels expressed in HEK293 cells. J. Pharmacol. Toxicol. Methods 2006, 54:164-172.
10. Erdemli G., Kim A.M., Ju H., Springer C., Penland R.C., Hoffmann P.K. Cardiac safety implications of hNav1.5 blockade and a framework for pre-clinical evaluation. Front. Pharmacol. 2012, 3:6.
11. Ericson A.-C., Kågström J., Laumola E.-L., Martinsson F., Eriksson A.B. Effects of hNaV1.5 blockers on the rat QRS interval. J. Pharmacol. Toxicol. Methods 2012, 160-205. (Abstract).
12. Gulden M., Seibert H. Influence of protein binding and lipophilicity on the distribution of chemical compounds in in vitro systems. Toxicol. in Vitro 1997, 11:479-483.
13. Gulden M., Morchel S., Seibert H. Factors influencing nominal effective concentrations of chemical compounds in vitro: cell concentration. Toxicol. in Vitro 2001, 15:233-243.
14. Gunnstrom M., Ababneh D., Webster W.S., Oakes D., Ritchie H. Antipsychotic drugs cause bradycardia in GD 13 rat embryos in vitro. Reprod. Toxicol. 2012, 34:443-450.
15. Harmer A.R., Abi-Gerges N., Easter A., Woods A., Lawrence C.L., Small B.G., Valentin J.P., Pollard C.E. Optimisation and validation of a medium-throughput electrophysiology-based hNav1.5 assay using IonWorks. J. Pharmacol. Toxicol. Methods 2008, 57:30-41.
16. Harmer A.R., Valentin J.P., Pollard C.E. On the relationship between block of the cardiac Na(+) channel and drug-induced prolongation of the QRS complex. Br. J. Pharmacol. 2011, 164:260-273.
17. Irisawa H., Brown H.F., Giles W. Cardiac pacemaking in the sinoatrial node. Physiol. Rev. 1993, 73:197-227.
18. Kawai C., Konishi T., Matsuyama E., Okazaki H. Comparative effects of three calcium antagonists, diltiazem, verapamil and nifedipine, on the sinoatrial and atrioventricular nodes. Experimental and clinical studies. Circulation 1981, 63:1035-1042.
19. Khan Niazi K.M., Ibrahim M.T., Nilsson M.F., Sköld A.C., Ling G., Nyström I. Robust signal generation and analysis of rat embryonic heart rate in vitro using Laplacian eigenmaps and empirical mode decomposition. Lecture Notes in Computer Science 2011, 523-530. Springer, Berlin/Heidelberg. P. Real, D. Diaz-Pernil, H. Molian-Abril, A. Berciano, W. Kropatsch (Eds.).
20. Khan K.M., Nilsson M.F., Danielsson B.R., Bengtsson E. Fully automatic heart beat rate determination in digital video recordings of rat embryos. Advances in Mass Data Analysis of Images and Signals in Medicine, Biotechnology, Chemistry and Food Industry 2008, 27-37. Springer-Verlag, Berlin Heidelberg. P. Perner, O. Salivetti (Eds.).
21. Kojima M., Sperelakis N. Calcium antagonistic drugs differ in ability to block the slow Na+ channels of young embryonic chick hearts. Eur. J. Pharmacol. 1983, 94:9-18.
22. Nilsson M.F., Danielsson C., Skold A.C., Johansson A., Blomgren B., Wilson J., Khan K.M., Bengtsson E., Kultima K., Webster W.S., Danielsson B.R. Improved methodology for identifying the teratogenic potential in early drug development of hERG channel blocking drugs. Reprod. Toxicol. 2010, 29:156-163.
23. Ono K., Kiyosue T., Arita M. Comparison of the inhibitory effects of mexiletine and lidocaine on the calcium current of single ventricular cells. Life Sci. 1986, 39:1465-1470.
24. Opie L.H. Pharmacological differences between calcium antagonists. Eur. Heart J. 1997, 18(Suppl. A):A71-A79.
25. Papadatos G.A., Wallerstein P.M., Head C.E., Ratcliff R., Brady P.A., Benndorf K., Saumarez R.C., Trezise A.E., Huang C.L., Vandenberg J.I., Colledge W.H., Grace A.A. Slowed conduction and ventricular tachycardia after targeted disruption of the cardiac sodium channel gene Scn5a. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:6210-6215.
26. Persson F., Andersson B., Duker G., Jacobson I., Carlsson L. Functional effects of the late sodium current inhibition by AZD7009 and lidocaine in rabbit isolated atrial and ventricular tissue and Purkinje fibre. Eur. J. Pharmacol. 2007, 558:133-143.
27. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., Siegl P.K., Strang I., Sullivan A.T., Wallis R., Camm A.J., Hammond T.G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 2003, 58:32-45.
28. Remme C.A., Verkerk A.O., Hoogaars W.M., Aanhaanen W.T., Scicluna B.P., Annink C., van den Hoff M.J., Wilde A.A., van Veen T.A., Veldkamp M.W., de Bakker J.M., Christoffels V.M., Bezzina C.R. The cardiac sodium channel displays differential distribution in the conduction system and transmural heterogeneity in the murine ventricular myocardium. Basic Res. Cardiol. 2009, 104:511-522.
29. Roger S., Le Guennec J.Y., Besson P. Particular sensitivity to calcium channel blockers of the fast inward voltage-dependent sodium current involved in the invasive properties of a metastastic breast cancer cell line. Br. J. Pharmacol. 2004, 141:610-615.
30. Rossner K.L., Freese K.J. Bupivacaine inhibition of l-type calcium current in ventricular cardiomyocytes of hamster. Anesthesiology 1997, 87:926-934.
31. Schroeder K., Neagle B., Trezise D.J., Worley J. Ionworks HT: a new high-throughput electrophysiology measurement platform. J. Biomol. Screen. 2003, 8:50-64.
32. Seibert H., Morchel S., Gulden M. Factors influencing nominal effective concentrations of chemical compounds in vitro: medium protein concentration. Toxicol. in Vitro 2002, 16:289-297.
33. Siebrands C.C., Schmitt N., Friederich P. Local anesthetic interaction with human ether-a-go-go-related gene (HERG) channels: role of aromatic amino acids Y652 and F656. Anesthesiology 2005, 103:102-112.
34. Skold A.C., Danielsson B.R. Developmental toxicity of the class III antiarrhythmic agent almokalant in mice. Adverse effects mediated via induction of embryonic heart rhythm abnormalities. Arzneimittelforschung 2000, 50:520-525.
35. Skold A.C., Wellfelt K., Danielsson B.R. Stage-specific skeletal and visceral defects of the I(Kr)-blocker almokalant: further evidence for teratogenicity via a hypoxia-related mechanism. Teratology 2001, 64:292-300.
36. Sugiyama A., Aye N.N., Katahira S., Saitoh M., Hagihara A., Matsubara Y., Hashimoto K. Effects of nonsedating antihistamine, astemizole, on the in situ canine heart assessed by cardiohemodynamic and monophasic action potential monitoring. Toxicol. Appl. Pharmacol. 1997, 143:89-95.
37. Webster W.S., Abela D. The effect of hypoxia in development. Birth Defects Res. C Embryo Today 2007, 81:215-228.
38. Webster W.S., Brown-Woodman P.D., Snow M.D., Danielsson B.R. Teratogenic potential of almokalant, dofetilide, and d-sotalol: drugs with potassium channel blocking activity. Teratology 1996, 53:168-175.
39. Wellfelt K., Skold A.C., Wallin A., Danielsson B.R. Teratogenicity of the class III antiarrhythmic drug almokalant. Role of hypoxia and reactive oxygen species. Reprod. Toxicol. 1999, 13:93-101.
40. Yi T., Wong J., Feller E., Sink S., Taghli-Lamallem O., Wen J., Kim C., Fink M., Giles W., Soussou W., Chen H.S. Electrophysiological mapping of embryonic mouse hearts: mechanisms for developmental pacemaker switch and internodal conduction pathway. J. Cardiovasc. Electrophysiol. 2012, 23:309-318.
41. Zhabyeyev P., Missan S., Jones S.E., McDonald T.F. Low-affinity block of cardiac K(+) currents by nifedipine. Eur. J. Pharmacol. 2000, 401:137-143.